论文部分内容阅读
我国药品监督管理局及美国FDA已于1998年底批准拉米夫定用于治疗慢性乙型肝炎,目前该药临床试用已逾4年,国内接受治疗者日增,积累了较丰富的经验,为此我国部分肝病专家于2000年3月12日对拉米夫定治疗乙型肝炎的指导意见进行了部分修改,以供参考。一、病人的选择 1.适合治疗对象:慢性乙型肝炎:按全国病毒性肝炎防治方案,确诊为慢性乙型肝炎,性别不限,年龄
China’s Drug Administration and the United States FDA approved lamivudine for the treatment of chronic hepatitis B at the end of 1998. At present, the drug has been used in clinical trials for more than 4 years. The number of patients receiving treatment in China has increased and accumulated rich experience. This part of China’s liver disease experts on March 12, 2000 lamivudine treatment of hepatitis B Guidance has been partially modified for reference. First, the patient’s choice 1. Suitable for treatment of objects: Chronic hepatitis B: According to the national viral hepatitis control programs, diagnosed as chronic hepatitis B, gender, age